The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications
Open accessAbstract
Gliomas are a heterogeneous group of brain tumors with distinct biological and clinical properties. Despite advances in surgical techniques and clinical regimens, treatment of high-grade glioma remains challenging and carries dismal rates of therapeutic success and overall survival. Challenges include the molecular complexity of gliomas, as well as inconsistencies in histopathological grading, resulting in an inaccurate prediction of disease progression and failure in the use of standard therapy. The updated 2016 World Health Organization (WHO) classification of tumors of the central nervous system reflects a refinement of tumor diagnostics by integrating the genotypic and phenotypic features, thereby narrowing the defined subgroups. The new classification recommends molecular diagnosis of isocitrate dehydrogenase (IDH) mutational status in gliomas. IDH-mutant gliomas manifest the cytosine-phosphate-guanine (CpG) island methylator phenotype (G-CIMP). Notably, the recent identification of clinically relevant subsets of G-CIMP tumors (G-CIMP-high and G-CIMP-low) provides a further refinement in glioma classification that is independent of grade and histology. This scheme may be useful for predicting patient outcome and may be translated into effective therapeutic strategies tailored to each patient. In this review, we highlight the evolution of our understanding of the G-CIMP subsets and how recent advances in characterizing the genome and epigenome of gliomas may influence future basic and translational research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
CpG Islands in vertebrate genomes
Gardiner-Garden, M., & Frommer, M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90689-9 · Cited by 3,353
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Sharma, S., Kelly, T. K., & Jones, P. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp220 · Cited by 2,637
CpG island methylator phenotype in colorectal cancer
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J.-P. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8681 · Cited by 2,523
The history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1279 · Cited by 2,344
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Self-citationInactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Ceccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S. M., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.028 · Cited by 2,189
Self-citationEUKARYOTIC CYTOSINE METHYLTRANSFERASES
Goll, M. G., & Bestor, T. H. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.010904.153721 · Cited by 2,063
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Glioma Groups Based on 1p/19q,IDH, and TERT Promoter Mutations in Tumors
Eckel-Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M. L., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,982
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus
Hark, A. T., Schoenherr, C. J., Katz, D. J., Ingram, R. S., Levorse, J. M., & Tilghman, S. M. (2000) · Nature · doi:10.1038/35013106 · Cited by 1,547
Hoadley, K. A., Yau, C., Wolf, D. M., Cherniack, A. D., Tamborero, D., Ng, S., Leiserson, M. D. M., Niu, B., McLellan, M. D., Uzunangelov, V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.049 · Cited by 1,499
SOX2 Functions to Maintain Neural Progenitor Identity
Graham, V., Khudyakov, J., Ellis, P., & Pevny, L. (2003) · Neuron · doi:10.1016/s0896-6273(03)00497-5 · Cited by 1,341
Insulator dysfunction and oncogene activation in IDH mutant gliomas
Flavahan, W. A., Drier, Y., Liau, B. B., Gillespie, S. M., Venteicher, A. S., Stemmer-Rachamimov, A. O., Suvà, M. L., & Bernstein, B. E. (2016) · Nature · doi:10.1038/nature16490 · Cited by 1,288
Editing DNA Methylation in the Mammalian Genome
Liu, X. S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., Shu, J., Dadon, D., Young, R. A., & Jaenisch, R. (2016) · Cell · doi:10.1016/j.cell.2016.08.056 · Cited by 1,224
Hartmann, C., Meyer, J., Balss, J., Capper, D., Mueller, W., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
Increased methylation variation in epigenetic domains across cancer types
Hansen, K. D., Timp, W., Bravo, H. C., Sabunciyan, S., Langmead, B., McDonald, O. G., Wen, B., Wu, H., Liu, Y., Diep, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.865 · Cited by 1,045
Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome
Sandoval, J., Heyn, H., Moran, S., Serra-Musach, J., Pujana, M. A., Bibikova, M., & Esteller, M. (2011) · Epigenetics · doi:10.4161/epi.6.6.16196 · Cited by 990
Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells
Suvà, M. L., Rheinbay, E., Gillespie, S. M., Patel, A. P., Wakimoto, H., Rabkin, S. D., Riggi, N., Chi, A. S., Cahill, D. P., Nahed, B. V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.030 · Cited by 944
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer
Baylin, S. B. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.687 · Cited by 929
The Sox Family of Transcription Factors: Versatile Regulators of Stem and Progenitor Cell Fate
Sarkar, A., & Hochedlinger, K. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.12.007 · Cited by 920
Interplay between the Cancer Genome and Epigenome
Shen, H., & Laird, P. W. (2013) · Cell · doi:10.1016/j.cell.2013.03.008 · Cited by 910
Going the Distance: A Current View of Enhancer Action
Blackwood, E. M., & Kadonaga, J. T. (1998) · Science · doi:10.1126/science.281.5373.60 · Cited by 836
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Epigenetic gene silencing in cancer: the DNA hypermethylome
Esteller, M. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm018 · Cited by 725
A vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 706
Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation
Wu, H., & Zhang, Y. (2011) · Genes & Development · doi:10.1101/gad.179184.111 · Cited by 672
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
Insulators: exploiting transcriptional and epigenetic mechanisms
Gaszner, M., & Felsenfeld, G. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1925 · Cited by 649
The NAD metabolome — a key determinant of cancer cell biology
Chiarugi, A., Dölle, C., Felici, R., & Ziegler, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3340 · Cited by 639
IDH1 and IDH2 mutations in gliomas
Cohen, A. L., Holmen, S. L., & Colman, H. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0345-4 · Cited by 629
Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry
Berdasco, M., & Esteller, M. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.10.005 · Cited by 618
Rivera, A. L., Pelloski, C. E., Gilbert, M. R., Colman, H., De La Cruz, C., Sulman, E. P., Bekele, B. N., & Aldape, K. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop020 · Cited by 434
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
Cairncross, J. G., Wang, M., Jenkins, R. B., Shaw, E. G., Giannini, C., Brachman, D. G., Buckner, J. C., Fink, K. L., Souhami, L., Laperriere, N. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3726 · Cited by 402
Alterations of immune response of non-small cell lung cancer with Azacytidine
Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H. P., Pan, X., Vendetti, F., VanCriekinge, W., DeMeyer, T., Du, Z., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1542 · Cited by 386
Melin, B. S., Barnholtz-Sloan, J. S., Wrensch, M. R., Johansen, C., Il'yasova, D., Kinnersley, B., Ostrom, Q. T., Labreche, K., Chen, Y., Armstrong, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3823 · Cited by 350
Bady, P., Sciuscio, D., Diserens, A.-C., Bloch, J., van den Bent, M. J., Marosi, C., Dietrich, P.-Y., Weller, M., Mariani, L., Heppner, F. L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1016-2 · Cited by 344
The future of epigenetic therapy in solid tumours—lessons from the past
Azad, N., Zahnow, C. A., Rudin, C. M., & Baylin, S. B. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.42 · Cited by 335
Integrated genomic characterization of IDH1-mutant glioma malignant progression
Bai, H., Harmancı, A. S., Erson-Omay, E. Z., Li, J., Coşkun, S., Simon, M., Krischek, B., Özduman, K., Omay, S. B., Sorensen, E. A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3457 · Cited by 329
Combining Epigenetic and Immunotherapy to Combat Cancer
Chiappinelli, K. B., Zahnow, C. A., Ahuja, N., & Baylin, S. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2125 · Cited by 309
Low-grade gliomas in adults: A review
Sanai, N., Chang, S., & Berger, M. S. (2011) · Journal of Neurosurgery · doi:10.3171/2011.7.jns101238 · Cited by 291
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
Labussière, M., Idbaih, A., Wang, X.-W., Marie, Y., Boisselier, B., Falet, C., Paris, S., Laffaire, J., Carpentier, C., Crinière, E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cf3a · Cited by 260
Mazor, T., Pankov, A., Johnson, B. E., Hong, C., Hamilton, E. G., Bell, R. J. A., Smirnov, I. V., Reis, G. F., Phillips, J. J., Barnes, M. J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.012 · Cited by 258
Correlation of immune phenotype with IDH mutation in diffuse glioma
Berghoff, A. S., Kiesel, B., Widhalm, G., Wilhelm, D., Rajky, O., Kurscheid, S., Kresl, P., Wöhrer, A., Marosi, C., Hegi, M. E., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox054 · Cited by 254
Turcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Wick, W., Meisner, C., Hentschel, B., Platten, M., Schilling, A., Wiestler, B., Sabel, M. C., Koeppen, S., Ketter, R., Weiler, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a95680 · Cited by 234
Wick, W., Roth, P., Hartmann, C., Hau, P., Nakamura, M., Stockhammer, F., Sabel, M. C., Wick, A., Koeppen, S., Ketter, R., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now133 · Cited by 227
DNA methylation and cellular reprogramming
De Carvalho, D. D., You, J. S., & Jones, P. A. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.08.003 · Cited by 222
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220
Epigenetic treatment of solid tumours: a review of clinical trials
Nervi, C., De Marinis, E., & Codacci-Pisanelli, G. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0157-2 · Cited by 213
Characterizing DNA methylation alterations from The Cancer Genome Atlas
Weisenberger, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69740 · Cited by 200
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
van den Bent, M. J., Looijenga, L. H. J., Langenberg, K., Dinjens, W., Graveland, W., Uytdewilligen, L., Sillevis Smitt, P. A., Jenkins, R. B., & Kros, J. M. (2003) · Cancer · doi:10.1002/cncr.11187 · Cited by 196
Wiestler, B., Capper, D., Sill, M., Jones, D. T. W., Hovestadt, V., Sturm, D., Koelsche, C., Bertoni, A., Schweizer, L., Korshunov, A., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1315-x · Cited by 194
Leu, S., von Felten, S., Frank, S., Vassella, E., Vajtai, I., Taylor, E., Schulz, M., Hutter, G., Hench, J., Schucht, P., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos317 · Cited by 192
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation
Duncan, C. G., Barwick, B. G., Jin, G., Rago, C., Kapoor-Vazirani, P., Powell, D. R., Chi, J.-T., Bigner, D. D., Vertino, P. M., & Yan, H. (2012) · Genome Research · doi:10.1101/gr.132738.111 · Cited by 176
Pan-cancer patterns of DNA methylation
Witte, T., Plass, C., & Gerhauser, C. (2014) · Genome Medicine · doi:10.1186/s13073-014-0066-6 · Cited by 175
Gittleman, H., Lim, D., Kattan, M. W., Chakravarti, A., Gilbert, M. R., Lassman, A. B., Lo, S. S., Machtay, M., Sloan, A. E., Sulman, E. P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now208 · Cited by 170
Sox2 Promotes Malignancy in Glioblastoma by Regulating Plasticity and Astrocytic Differentiation
Berezovsky, A. D., Poisson, L. M., Cherba, D., Webb, C. P., Transou, A. D., Lemke, N. W., Hong, X., Hasselbach, L. A., Irtenkauf, S. M., Mikkelsen, T., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.03.006 · Cited by 166
Molecular classification of gliomas
Masui, K., Mischel, P. S., & Reifenberger, G. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00006-2 · Cited by 137
van den Bent, M. J., Gravendeel, L. A. M., Gorlia, T., Kros, J. M., Lapre, L., Wesseling, P., Teepen, J. L. J. M., Idbaïh, A., Sanson, M., Smitt, P. A. E. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1274 · Cited by 127
Epigenetic modifications of the immune system in health and disease
Obata, Y., Furusawa, Y., & Hase, K. (2015) · Immunology and Cell Biology · doi:10.1038/icb.2014.114 · Cited by 126
New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
Dimitrov, L., Hong, C. S., Yang, C., Zhuang, Z., & Heiss, J. D. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.11047 · Cited by 117
Biological significance of the CpG island methylator phenotype
Suzuki, H., Yamamoto, E., Maruyama, R., Niinuma, T., & Kai, M. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.007 · Cited by 113
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
Chen, R., Cohen, A. L., & Colman, H. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0418-0 · Cited by 105
Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy
Maio, M., Covre, A., Fratta, E., Giacomo, A. M. D., Taverna, P., Natali, P. G., Coral, S., & Sigalotti, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2914 · Cited by 102
Wiestler, B., Claus, R., Hartlieb, S. A., Schliesser, M. G., Weiß, E. K., Hielscher, T., Platten, M., Dittmann, L. M., Meisner, C., Felsberg, J., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not043 · Cited by 95
Advances in immunotherapy for the treatment of glioblastoma
Tivnan, A., Heilinger, T., Lavelle, E. C., & Prehn, J. H. M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2299-2 · Cited by 91
Wiestler, B., Capper, D., Hovestadt, V., Sill, M., Jones, D., Hartmann, C. J., Felsberg, J., Platten, M., Feiden, W., Keyvani, K., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou138 · Cited by 89
DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension
Licht, J. D. (2015) · Cell · doi:10.1016/j.cell.2015.08.005 · Cited by 69
Mur, P., Mollejo, M., Ruano, Y., de Lope, Á. R., Fiaño, C., García, J. F., Castresana, J. S., Hernández‐Laín, A., REY, J. A., & Meléndez, B. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1130-9 · Cited by 58
The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation
Miller, B., Sánchez-Vega, F., & Elnitski, L. L. (2016) · Biomolecules · doi:10.3390/biom6040045 · Cited by 58
Sánchez-Vega, F., Gotea, V., Margolin, G., & Elnitski, L. L. (2015) · Epigenetics & Chromatin · doi:10.1186/s13072-015-0007-7 · Cited by 54
Lee, S., & Wiemels, J. L. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1038 · Cited by 54
Mur, P., de Lope, Á. R., Diaz-Crespo, F. J., Hernández‐Iglesias, T., Ribalta, T., Fiaño, C., García, J. F., REY, J. A., Mollejo, M., & Meléndez, B. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1738-9 · Cited by 53
Feng, J., Yan, P.-F., Zhao, H., Zhang, F., Zhao, W., & Feng, M. (2016) · BioMed Research International · doi:10.1155/2016/1450843 · Cited by 53
Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas
Siegal, T. (2015) · Advances and technical standards in neurosurgery · doi:10.1007/978-3-319-21359-0_4 · Cited by 52
Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with Immunotherapy
Park, J., Thomas, S., & Münster, P. N. (2015) · Epigenomics · doi:10.2217/epi.15.16 · Cited by 48
Wick, W., Roth, P. A., Wiestler, B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2001 · Cited by 45
Pharmacological DNA demethylation: Implications for cancer immunotherapy
Roulois, D., Yau, H. L., & Carvalho, D. D. D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1090077 · Cited by 31
DNA methylation in adult diffuse gliomas
Leblanc, V., & Marra, M. A. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw019 · Cited by 22
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Taylor, J. W., Chi, A. S., & Cahill, D. P. (2013) · PubMed · Cited by 12
Relation between Established Glioma Risk Variants and DNA Methylation in the Tumor
Dahlin, A. M., Wibom, C., Ghasimi, S., Brännström, T., Andersson, U., & Melin, B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163067 · Cited by 12
Sahebjam, S., McNamara, M. G., & Mason, W. P. (2013) · CNS Oncology · doi:10.2217/cns.13.26 · Cited by 10
Cited by
Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 592
Diffuse Glioma Heterogeneity and Its Therapeutic Implications
Nicholson, J. G., & Fine, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1474 · Cited by 460
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Defining Driver DNA Methylation Changes in Human Cancer
Pfeifer, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041166 · Cited by 323
van den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae107 · Cited by 88
“128 Within the IDH-mutant astrocytoma tumor subgroup, 2 major methylation subgroups have been identified by genome-wide DNA methylation profiling: Glioma-CpG Island Methylator Phenotype (G-CIMP)-low and G-CIMP-high, with G-CIMP-low tumors displaying lower levels of genome-wide DNA-methylation…”
BackgroundSelf-citation
Metadata
- Authors
- Malta, T. M., de Souza, C. F., Sabedot, T. S., Silva, T. C., Mosella, M. S., Kalkanis, S. N., Snyder, J., Castro, A. V. B., & Noushmehr, H.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-09-26
- Volume
- 20
- Issue
- 5
- Pages
- 608-620
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2951388646
- Cited by
- 302
- References
- 99
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.